Table 3.

Univariate and multivariable analysis for HBV reactivation in lung cancer patients receiving tyrosine kinase inhibitor treatment only.

Variable	Total	Univariate Analysis		Multivariable Analysis
	n = 349	Hazard Ratio (95% CI)	p Value	Hazard Ratio (95% CI)	p Value
Age		0.96 (0.92–1.00)	0.067	0.97 (0.93–1.01)	0.164
Gender
Female	204	Reference		Reference
Male	145	1.63 (0.61–4.35)	0.327	1.18 (0.35–3.97)	0.792
Smoking habit
Never smoker	244	Reference		Reference
Ever smoker	75	2.04 (0.74–5.62)	0.167	2.73 (0.72–10.32)	0.140
Tyrosine kinase inhibitor
Gefitinib	85	Reference		Reference
Erlotinib	141	0.52 (0.17–1.62)	0.262	0.32 (0.10–1.04)	0.059
Afatinib	77	0.43 (0.11–1.74)	0.239	0.33 (0.08–1.42)	0.135
Osimertinib	23	0.56 (0.07–4.70)	0.596	0.35 (0.04–3.42)	0.365
HBV serology
Negative HBsAg	276	Reference		Reference
Positive HBsAg	73	62.20 (8.21–471.08)	<0.001	53.77 (7.00–412.90)	<0.001